


Licensed Swiss Pharmaceutical Wholesale Business





Licensed Swiss Pharmaceutical Wholesale Business

This Licensed Pharmaceutical Wholesale Business is a pioneering organization in the pharmaceutical industry, committed to enhancing the quality of life through innovative healthcare solutions. Established with a vision to address unmet medical needs, the company exemplifies excellence in research and development, focusing on the creation of unique therapies that cater to rare and complex diseases.

A Swiss-registered pharmaceutical wholesaler holds a valuable Good Distribution Practice (GDP) authorization from Swissmedic. The company possesses comprehensive wholesale licensing for pharmaceutical products, enabling both national and international trade operations, including import, export, and raw materials wholesale activities. Operating with a small team from its Winterthur location, the business is structured to serve the global pharmaceutical market.

Strategic Value Proposition

The primary asset of the company is its GDP license, which acts as a significant barrier to entry in the pharmaceutical wholesale sector. Total investment to date amounts to CHF 230,566.18, covering complete operational setup and regulatory compliance. The business offers flexibility in acquisition structure, with options for a financed complete purchase.

Swiss Pharmaceutical Industry & Tax Advantages

Switzerland's pharmaceutical sector is a premier global hub, home to industry leaders and renowned for its quality and regulatory excellence. A licensed operation benefits from this prestigious ecosystem, where pharmaceutical products command premium pricing and enjoy streamlined access to both EU and global markets. The Swiss regulatory framework, while stringent, offers significant advantages through mutual recognition agreements with major markets, facilitating international trade operations.

From a tax perspective, Switzerland provides compelling advantages for pharmaceutical operations. The country's corporate tax rates are among Europe's most competitive, typically ranging from 11.9% to 21.6%, depending on the canton. Switzerland's patent box regime allows for preferential taxation of patent-related income, with up to 90% tax relief on qualifying income. Additionally, companies can benefit from R&D super-deductions and tax-efficient handling of intellectual property rights. The stability and transparency of the Swiss tax system, combined with an extensive network of double taxation treaties, create an optimal environment for international pharmaceutical trade and investment.

The GDP authorization's scope covers comprehensive pharmaceutical wholesale operations, positioning the acquirer for immediate market entry into the regulated pharmaceutical distribution sector. While currently pre-revenue, the established regulatory framework and operational infrastructure provide a turnkey solution for entering the Swiss and international pharmaceutical wholesale market.

Keypoints

Registration Address: Winterthur, Swiss

Type of Entity: GmbH

Banking Relationship: Zürcher Kantonal Bank

Regulatory Licence: Swissmedic GDP

GROSS REVENUE

\$0

EBITDA

\$0

BUSINESS TYPE

Pharma

COUNTRY

Switzerland

BUSINESS ID

L#20250834

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM